Bryan Stuart
Chief Executive Officer presso Atavistik Bio, Inc.
Patrimonio netto: 18 380 $ in data 31/03/2024
Profilo
Bryan E Stuart is currently the Chief Executive Officer & Director at Atavistik Bio, Inc. He previously served as the President & Chief Executive Officer at Kastle Therapeutics LLC, Yarra Therapeutics LLC, and Fulcrum Therapeutics, Inc. He was also the Chief Corporate Development Officer at EKR Therapeutics, Inc. and the VP-Corporate Development, Merger & Acquisitions at OVATION Pharmaceuticals, Inc. Additionally, he served as the Chief Business Officer at Civitas Therapeutics, Inc. Mr. Stuart received his undergraduate degree from the University of Illinois and his MBA from Kellogg School of Management.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
31/03/2023 | 1 947 ( 0.00% ) | 18 380 $ | 31/03/2024 |
Posizioni attive di Bryan Stuart
Società | Posizione | Inizio |
---|---|---|
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | Chief Executive Officer | 17/07/2023 |
Precedenti posizioni note di Bryan Stuart
Società | Posizione | Fine |
---|---|---|
FULCRUM THERAPEUTICS, INC. | Chief Executive Officer | 02/01/2023 |
Yarra Therapeutics LLC | Chief Executive Officer | 01/08/2018 |
Kastle Therapeutics LLC
Kastle Therapeutics LLC Medical/Nursing ServicesHealth Services Kastle Therapeutics LLC develops therapeutics targeted towards patients with high unmet medical needs. The company is headquartered in Chicago, IL. | Chief Executive Officer | 01/11/2017 |
Civitas Therapeutics, Inc.
Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Corporate Officer/Principal | 01/10/2014 |
EKR Therapeutics, Inc.
EKR Therapeutics, Inc. Hospital/Nursing ManagementHealth Services EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. | Corporate Officer/Principal | 01/06/2012 |
Formazione di Bryan Stuart
University of Illinois | Undergraduate Degree |
Kellogg School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
FULCRUM THERAPEUTICS, INC. | Health Technology |
Aziende private | 6 |
---|---|
EKR Therapeutics, Inc.
EKR Therapeutics, Inc. Hospital/Nursing ManagementHealth Services EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. | Health Services |
OVATION Pharmaceuticals, Inc.
OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Health Technology |
Civitas Therapeutics, Inc.
Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Health Technology |
Kastle Therapeutics LLC
Kastle Therapeutics LLC Medical/Nursing ServicesHealth Services Kastle Therapeutics LLC develops therapeutics targeted towards patients with high unmet medical needs. The company is headquartered in Chicago, IL. | Health Services |
Yarra Therapeutics LLC | |
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | Health Technology |
- Borsa valori
- Insiders
- Bryan Stuart